Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P 1 , with an IC 50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P 1 -mediated signal transduction with high potency ( EC 50 =5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation.
Products | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > LPL Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.